Peregrine Pharmaceuticals reported $142.31M in Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Agenus AGEN:US $ 13.7M 0.48M
Amgen AMGN:US $ 36522M 332M
AstraZeneca AZN:LN 2425311.81M 57309.55M
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Bristol Myers Squibb BMY:US $ 42060M 2912M
Celldex Therapeutics CLDX:US $ 0M 0M
Chemocentryx CCXI:US $ 23.72M 0.04M
Eli Lilly And LLY:US $ 16813.8M 305M
GlaxoSmithKline GSK:LN 2211100M 1121700M
Intrexon XON:US $ 198.67M 2.79M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Macrogenics MGNX:US $ 0M 0M
Mannkind MNKD:US $ 376.46M 8.08M
Novartis NOVN:VX SF 31031M 244M
Novavax NVAX:US $ 448.43M 7.93M
Peregrine Pharmaceuticals PPHM:US $ 142.31M 0.14M
Repligen RGEN:US $ 283.71M 0.44M
Xencor XNCR:US $ 0M 0M